89bio Inc (ETNB)
8.20
-0.38
(-4.43%)
USD |
NASDAQ |
Apr 25, 13:07
89bio Free Cash Flow (Quarterly): -34.29M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -34.29M |
| September 30, 2023 | -30.36M |
| June 30, 2023 | -34.45M |
| March 31, 2023 | -30.08M |
| December 31, 2022 | -27.10M |
| September 30, 2022 | -14.82M |
| June 30, 2022 | -14.83M |
| March 31, 2022 | -24.35M |
| December 31, 2021 | -28.27M |
| September 30, 2021 | -13.47M |
| Date | Value |
|---|---|
| June 30, 2021 | -20.12M |
| March 31, 2021 | -14.99M |
| December 31, 2020 | -14.03M |
| September 30, 2020 | -12.96M |
| June 30, 2020 | -11.57M |
| March 31, 2020 | -7.813M |
| December 31, 2019 | -11.24M |
| September 30, 2019 | -6.205M |
| June 30, 2019 | -3.982M |
| March 31, 2019 | -4.169M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-34.45M
Minimum
Jun 2023
-3.982M
Maximum
Jun 2019
-18.68M
Average
-14.83M
Median
Jun 2022
Free Cash Flow (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | -80.97M |
| Akero Therapeutics Inc | -48.63M |
| Viking Therapeutics Inc | -17.64M |
| Galectin Therapeutics Inc | -4.702M |
| Terns Pharmaceuticals Inc | -19.36M |